DiaMedica Therapeutics Inc. (NASDAQ: DMAC ) will release earnings for its fourth quarter after the closing bell on Monday, March 30.
Analysts expect the Minneapolis, Minnesota-based company to report quarterly loss of 18 cents per share. That's the same as the 18 cents loss recorded in the year-ago period, according to Benzinga Pro .
On March 5, DiaMedica Therapeutics received Health Canada clearance to initiate Phase 2 study of DM199 in Preeclampsia.
Shares of DiaMedica Therapeutics fell 0.9% to close at $6.79 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
Considering buying DMAC stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Earnings News Price Target Markets Analyst Ratings Trading Ideas Expert Ideas Top Wall Street Forecasters